DBV Technologies S.A. (DBVT) Stock Score, Valuation & Financial Research

DBV Technologies S.A. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DBVT

DBV Technologies S.A. does not currently have a complete Wall Street Score. The stored market price is USD 9.98. These figures are a research snapshot, not a buy or sell recommendation.

What DBV Technologies S.A. does

DBV Technologies S.A., a biopharmaceutical firm based in Montrouge, France, operates at the clinical stage, focusing on the research and development of epicutaneous immunotherapy solutions. Its flagship product, Viaskin Peanut, has completed Phase III clinical trials as an immunotherapy for peanut allergies in children aged 4 to 11, adolescents, and adults. The company's pipeline also includes Viaskin Milk, currently undergoing Phase I/II clinical trials for the treatment of Immunoglobulin E (IgE)-mediated cow's milk protein allergy, and Viaskin Egg, which is in pre-clinical development for hen's egg allergy. Additionally, DBV Technologies is developing a booster vaccine targeting Bordetella pertussis. Beyond these, the company explores earlier-stage research for a respiratory syncytial virus vaccine and potential therapies for Crohn's disease, celiac disease, and type I diabetes. In partnership with Nestlé Health Science, it is developing MAG1C, a user-friendly atopy patch test for diagnosing non-IgE mediated cow's milk protein allergy in infants and toddlers. DBV Technologies S.A. was established in 2002.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

DBV Technologies is a late-stage biopharmaceutical company that generates revenue primarily through research tax credits and collaborative agreements. The company is currently in the development phase, focusing on its proprietary Viaskin patch technology for food allergies, and does not yet have commercialized products generating recurring product sales revenue.

Products and services

The company is developing the Viaskin patch, an epicutaneous immunotherapy platform designed to treat food allergies, including its lead candidate, Viaskin Peanut.

Brands and product families

Viaskin — Proprietary epicutaneous immunotherapy patch technology platform. Source

Customer types

Patients with food allergies.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of clinical trial materials and potential future commercial supply. Source

Business strengths to evaluate

Proprietary Viaskin patch technology platform Source

Business risks and research considerations

History of significant losses and anticipation of continued losses Source
Dependence on successful development of Viaskin technology Source
Unpredictable clinical trial outcomes and high risk of failure Source
Need for additional funding to continue operations Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DBVT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 9.98
Market capitalization:: 238.74M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -175.85M
Free cash flow:: USD -121.71M
Cash:: USD 174.9M
Total debt:: USD 21M
EPS:: USD -1.98

What stands out

Free cash flow is USD -121.71M, negative for the stored period.
The balance sheet shows USD 174.9M of cash versus USD 21M of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 153.9M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DBVT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can DBVT fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is DBVT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for DBVT to reach sustainable profitability?
What does the current share basis reconciled warning mean for the reliability or interpretation of DBVT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DBVT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.